本文へ移動
cccskills
無料GitHub で公開

endo-pa-screen-hypertension

Determines whether to screen a patient with hypertension for primary aldosteronism based solely on the presence of hypertension. Use when a clinician asks whether to screen a hypertensive patient for PA, triggered by phrases such as "should we screen for aldosteronism" or "evaluate for secondary hypertension".

インストール方法を見る

含まれるファイル(1)

  • SKILL.md1.9 KB

SKILL.md(原文)

インストールする前に、エージェントに与えられる指示の中身を確認できます。

Screen for primary aldosteronism in hypertensive patients

STEP 1 — Gather Information

Confirm hypertension diagnosis using office BP ≥140/90 mmHg on ≥2 occasions, ambulatory BP, or home BP averages; document current antihypertensive medications.

STEP 2 — Rule In / Rule Out

If hypertension is present, proceed to screen for PA; if hypertension is absent, do not screen for PA based on this guideline.

STEP 3 — Classify or Stratify

Classify the patient as indicated for PA screening per Recommendation 1 (all hypertensives should be screened).

STEP 4 — Decide

Order morning seated serum/plasma aldosterone and plasma renin concentration (or activity) with avoidance of dietary sodium restriction prior to testing; measure serum potassium for accurate interpretation.

Clinical Guardrails / Mimics / Pitfalls

Do not rely on hypokalemia to rule out screening; do not delay screening until complications or resistant hypertension develop; avoid withholding screening due to mild or controlled hypertension; consider interfering medications (e.g., β‑blockers, ACEi/ARBs) but still screen, repeating if needed after medication withdrawal.

Concrete Clinical Example

A 58‑year‑old with stage 2 hypertension (BP 165/100 mmHg) on lisinopril and hydrochlorothiazide asks whether they should be screened for PA. According to the guideline, screen all hypertensives, so order aldosterone and renin levels.

Source: Primary Aldosteronism: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2025, DOI: 10.1210/clinem/dgaf284

レビュー

まだレビューはありません。使ってみた感想をお寄せください。

同じリポジトリのスキル

概要と使いどころ

Guide pump setting adjustments for the MiniMed 780G system based on CareLink data, using Medtronic's 3-step follow-up workflow. Use when a clinician has CareLink data for a 780G patient and wants to know what to change — which setting, by how much, and how to program it. Triggers include: "what do I adjust", "how to fix high TIR", "how to reduce hypos", "adjust ICR/ISF/basal", "SmartGuard settings", "780G pump settings review", or any question about optimising 780G therapy after reviewing a download.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL132026年10月5日 更新

Performs corticotropin stimulation test to diagnose adrenal insufficiency when morning cortisol is indeterminate (3-15 µg/dL). Triggers include morning cortisol 3-15 µg/dL requiring further AI testing.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL132026年10月5日 更新

Administers immediate parenteral injection of 50–100 mg hydrocortisone for suspected adrenal crisis secondary to adrenal insufficiency. Triggers include hypotension, hypoglycemia, or acute illness in a patient with known adrenal insufficiency.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL132026年10月5日 更新

Clinicians educate adrenal insufficiency patients taking nondexamethasone glucocorticoids who initiate enzyme-inducing antiepileptic drugs about early signs of adrenal insufficiency. Trigger when an AI patient on nondexamethasone GC starts an enzyme-inducing AED such as phenytoin, carbamazepine, or oxcarbazepine.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL132026年10月5日 更新

In central hypothyroidism patients receiving levothyroxine who initiate enzyme‑inducing antiepileptic drugs, the guideline recommends checking free T4 at least 6 weeks after AED start and increasing the levothyroxine dose if free T4 falls below the target range. Triggers include: central hypothyroidism patient on levothyroxine starting antiepileptic drug such as phenytoin, carbamazepine, or oxcarbazepine.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL132026年10月5日 更新

Applies serum cortisol cutoffs (<3 μg/dL indicates central adrenal insufficiency; >15 μg/dL likely excludes it) when evaluating morning cortisol for suspected adrenal insufficiency. Triggers include morning cortisol measurement in suspected AI and use when interpreting morning cortisol levels for adrenal insufficiency workup.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL132026年10月5日 更新

dromlakhani のスキルをすべて見る

このスキルの問題を報告する